u.s. biotech werck

Genta shares , over $15 in may have just hit $1.30 on a 50% drop last night on news from their Genansense trial . [Yesterday it was announced that Genasense from GNTA just succeeded in hitting the primary endpoint in its leukemia trial, but missed the secondary endpoints. Look further and you see that the primary endpoint was objective response (tumor reduction), and median survival was one of the secondary endpoints. Now look at GNTA's stock price. Took a hit because Sanofi/Aventis saw the results and dropped Genasense like a hot potato. NO IMPROVEMENT IN SURVIVAL. That's what flies at the FDA, and Genasense is grounded.]
I hear it cost SNY/AVE 10m to walk away .
It is encourageing to have the knowledge that Solbec have seen evidence of increased survival in their target cancers , even before the first clinical trial , from amongst their special access patients .